BHB & CAR-T for Lymphomas

This study is looking at whether adding a dietary supplement called R-1,3-Butanediol (which turns into BHB in your body) is safe and can be tolerated by people with large B-cell lymphoma (LBCL). You could be eligible if you are 18 or older, have LBCL, and are planning to receive standard CAR-T cell therapy (Yescarta or Kymriah). The main goal is to see if R-1,3-Butanediol is safe and tolerable when given with CAR-T therapy. The study will also look at how this supplement might affect your gut bacteria and blood cells. The current status of this study is unclear, and it plans to enroll 5 participants.

Study design: This is an interventional study with an unclear phase, planning to enroll 5 participants.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Safety and tolerability will be measured from CAR-T infusion to day 28 after CAR-T.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

BHB & CAR-T for Lymphomas

Recruiting

NAAges 18+InterventionalTreatment

Abramson Cancer Center at Penn Medicine

~5 participants

Updated 2026-02-23 on ClinicalTrials.gov

What's tested:R-1,3-Butanediol

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Safety and tolerability

Measured over From CART infusion to day 28 visit after CART

Conditions

Large B-cell Lymphoma

Where it's being run

1 sites across 1 states

Pennsylvania1

Study leadership

Elise Chong, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center at the University of Pennsylvania

Who to contact

Brittany Koch, MPH

[email protected]

215-615-4312

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age of 18 years or older

History of pathologically-confirmed large B-cell lymphoma (LBCL)

Planned treatment with a commercially available anti-CD19 CAR-T product (Yescarta or Kymriah)

Eligible for and with adequate organ function (investigator discretion) and performance status (ECOG PS 2 or less) for standard of care, anti-CD19 CAR-T

Not enrolled on a clinical trial of bridging therapy prior to CAR-T

Patients must have a PET/CT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra- nodal lesions in largest dimension by low-dose computerized tomography \[CT\] scan with FDG-uptake ≥ liver) documented prior to leukapheresis for CAR-T manufacturing

Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator

Can provide informed consent

Willing to comply with all study procedures and available for the duration of the study

Exclusion

Subject is pregnant or breast feeding

History of allergy to energy drinks

History of inflammatory bowel disease

History of type 1 diabetes mellitus or requirement for insulin

History of chronic kidney disease with an eGFR \< 30 mL/min/1.73m2

Additional second primary malignancy for which the subject is receiving active therapy or that will impede the ability of the investigator to assess lymphoma response

What this trial measures

Safety and tolerabilityFrom CART infusion to day 28 visit after CART
Assess number and severity of adverse events as well as number of patients who complete treatment

Trialytics